Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy
View Patent ↗Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.
1. A method of treating a patient suffering from gout having a serum uric acid (SUA) level of 6 mg/dl or less, and reducing the incidence of infusion reaction in said patient, the method comprising:
administering to said patient, a therapeutically effective amount of a PEGylated uricase every two weeks;
after a first period of time, determining the SUA level of said patient, and
if said SUA level of the patient is maintained below 6 mg/dl, continuing said administration of PEGylated uricase every two weeks, whereas if said SUA level of the patient is above 6 mg/dl, discontinuing said administration thereby reducing the incidence of infusion reaction in said patient, wherein said patient previously received ineffective allopurinol therapy or has a medical history in which allopurinol therapy is contraindicated.
2. The method according to claim 1 , wherein said SUA level is determined after 24 hours but within 2 weeks of said administering.
3. The method according to claim 1 , wherein said first period of time is two weeks.
4. The method according to claim 1 , wherein said gout is refractory.
5. The method according to claim 1 , wherein said gout is chronic or tophaceous.
6. The method according to claim 1 , wherein said PEGylated uricase is administered intravenously.